FDA clears antimicrobial blood pressure cuff:
This article was originally published in Clinica
Executive Summary
Vital Signs has received US FDA 510(k) clearance to market its antimicrobial-treated, single-patient-use blood pressure cuff. The Cuffable Plus device, which is impregnated with an antimicrobial agent, could help combat the cross contamination that leads to hospital-acquired infections, said the Totowa, New Jersey-based company. Noting that the US market for single-patient-use blood pressure cuffs is approaching $30 million, Vital said its antimicrobial enhancement would help it advance its number two market position.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.